x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

science life sciences

All Episodes

00:10:21

Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/14

Daraxonrasib slashes death risk 60% in metastatic pancreaticcancer Phase 3 — Revolution Medicines leads a $1.5B offering wave. Neurocrine acquires Soleno for $2.9B, Regeneron enters radiopharma via Telix, and Travere nabs the first-ever FSGS approval with Filspari.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, daraxonrasib, Revolution Medicines, RVMD, pancreatic cancer, RASolute 302,

en-us

00:14:08

Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/13

FDA issues second CRL for Replimune's melanoma therapy RP1 —stock drops 20%, single-arm trial debate sharpens. Sun Pharma's $12B all-cash bid for Organon, Amgen's 77% proptosis response in subcutaneous TEPEZZA Phase 3, Lilly launches Foundayo, and AACR 2026 preview.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Replimune, RP1,vusolimogene oderparepvec, melanoma, complete response

en-us

00:10:44

Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/09

Lilly launches Foundayo to challenge Novo Nordisk in oralGLP-1s with a GoodRx access play. Gilead acquires ADC specialist Tubulis for $3.15B upfront in its third deal since February. Plus FDA lifts MacroGenics hold, AbbVie sues over 340B, and Vanda targets GLP-1 side effects with theThetis trial.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Foundayo, oral GLP-1, Novo Nordisk, Gilead Sciences,

en-us

00:09:58

Apr 07, 2026 | Pharma Tariffs Hit 100% with Major...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/08

100% tariffs on branded drug imports took effect — but thecarve-outs may matter more than the rate. Gilead acquires ADC maker Tubulis for $3.15B upfront (up to $5B), Merck launches its $6B Terns tender offer after cutting the bid by $1B on data concerns, and Novo Nordisk rolls out Wegovy HD7.2mg nationwide. Plus FDA Commissioner Makary's FY2027 budget proposals and Corbus secures its CRB-701 registration path.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials,

en-us

00:09:31

Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/08

Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B after data peek, and Sanofi's bispecific lunsekimig hits in asthma but misses in eczema. Plus Novo launches high-dose Wegovy.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Gilead, Tubulis, ADC, antibody-drug conjugate, Neurocrine, Soleno, Prader-Willi,

en-us

00:13:40

Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/06

Trump's 100% tariff on patented drugs reshapes pharmastrategy—tiered exemptions create winners and losers. Lilly's Foundayo approved; Novo fires back with ORION data showing oral Wegovy's tolerability edge. Plus Biogen-Apellis, Q1's $47B M&A wave, and the first R&Dpipeline contraction in 30 years.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, pharma tariff, Trump

en-us

00:10:41

Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/04

Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight days as R&D pipeline shrinks for first time in 30 years. Lilly's Foundayo approved, oral obesity war heats up. ORIC crashes on dose selection.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, drug tariffs, Section 232, Eli Lilly, Foundayo,

en-us

00:10:16

Apr 02, 2026 | Trump's 100% Drug Tariff Splits...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/03

Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) andBiogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo,

en-us

00:10:19

Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/02

Lilly's Foundayo becomes the first oral GLP-1 approved forobesity in the U.S. — LLY jumps 3.78%. Immunovant's batoclimab misses both Phase 3 endpoints in thyroid eye disease. Plus: Merck-Infinimmune $838M antibody deal, Blackstone's record $6.3B life sciences fund, and the WhiteHouse readies 100% tariffs on imported brand-name drugs.www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,

en-us

00:09:30

Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/04/01

Eli Lilly acquires Centessa Pharmaceuticals for up to $7.8B,targeting narcolepsy via orexin agonists as part of pharma's $25.5B eight-day buying spree. Biogen bets $5.6B on Apellis complement therapies. FDA warns of 8deaths linked to Amgen's Tavneos liver safety signal.visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, Centessa Pharmaceuticals, Biogen, Apellis

en-us

00:09:00

Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/31

United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 38% stock crash on REVEAL-1 data, Lilly's $115M upfront AI deal with Insilico Medicine, BridgeBio's 54-month ATTR-CM survivaldata, Biogen's Spinraza HD FDA approval, and CBER untitled letters hitting four major companies.Visit us at www.thepharmacloseout.com Pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals,

en-us

00:13:38

Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/30

Eli Lilly signs $2.75B biobucks deal with Insilico Medicinefor AI-discovered oral therapeutics. AAD 2026 brings 52-week ICOTYDE, zasocitinib Phase 3 psoriasis data, and Sanofi amlitelimab Q12W dosing in atopic dermatitis. Plus HI-PEITHO PE results from ACC and Merck's WINREVAIRCADENCE proof-of-concept.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Eli Lilly, InsilicoMedicine, AI drug

en-us

00:10:35

Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/28

FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin, after a three-year regulatory journey. Plus Novartis bets $2B on a next-gen Xolair successor, Otsuka acquires Transcend for $700M upfront, andAstraZeneca's tozorakimab delivers dual Phase 3 wins in COPD. Rocket Pharmaceuticals lands its first gene therapy approval for severe LAD-I.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The

en-us

00:09:27

Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/27

Wave Life Sciences plunges 58% after WVE-007 higher-doseobesity data fails to separate from lower dose. CVC Capital Partners offers €52/share ($12.6B) to take Recordati private. Plus: Kodiak's Phase 3 GLOW2 diabetic retinopathy win, Corcept's relacorilant approval in ovarian cancer, and FDA "America First" user fee pushback.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:09:19

Mar 25, 2026 | Merck's $6.7B Terns Acquisition for...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/26

Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma

en-us

00:09:23

Mar 24, 2026 | ImmunityBio's Third FDA Warning...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/25

ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medicines for $1.68B upfront to build autoimmune bispecific franchise. UCB commits $2B to first U.S. biologics plant in Georgia.Visit us at: www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, ImmunityBio, IBRX, ANKTIVA, FDA warning letter, Gilead, Ouro Medicines,

en-us

00:09:16

Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%;...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/23

Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Arikayce ENCORE Phase 3b hits primary endpoint in MAC lung disease. Dizal Zegfrovy pressures J&J's Rybrevant with first-line NSCLC data. Follow us at: https://thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Apogee Therapeutics, zumilokibart, atopic dermatitis,

en-us

00:11:14

Mar 22, 2026 | Abbott's $21B Exact Sciences Deal...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/23

Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron PDUFA slips to April 10. Plus: GSK's Lynavoy, Pfizer's TALAPRO-3 data, and Genentech's emugrobart setback. Full week-in-review.pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Abbott, Exact Sciences, Cologuard, Oncotype DX, Novo Nordisk, Wegovy HD,

en-us

00:09:42

Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/21

Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins first immunotherapy combo approval in frontline Hodgkin lymphoma, GSK's Lynavoy becomes first drug for cholestatic pruritus in PBC, and Pfizer's TALAPRO-3 clears Phase 3 in prostate cancer.Visit us at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma

en-us

00:10:32

Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All...

The Pharma Closeout | Daily Pharmaceutical &... ·

2026/03/20

Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same day Novo's Wegovy HD wins record-fast CNPV approval. Plus Collegium acquires Azstarys for $650M, Pfizer's Talzenna wins in prostatecancer, and Lynavoy gets an early FDA nod.Visit the website at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

121 results

Similar Podcasts

Mothman Podcast

Mothman Podcast

Autobiography of an Electron

Charles R. Gibson

This is a Science Show

Dustin Driver

Get Into Gate: A Stargate Podcast

Get Into Geek

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group